二甲双胍抗肿瘤效应的基础与临床研究进展

二甲双胍(Metformin)是一种胰岛素增敏剂,临床上主要用于2型糖尿病的治疗。越来越多的证据表明,二甲双胍能够发挥抗肿瘤效应,它通过活化磷酸腺苷蛋白激酶(AMPK),阻断哺乳动物雷帕霉素靶蛋白(m TOR)信号通路抑制肿瘤细胞的生长,并且参与细胞周期、凋亡、血管新生等多种生物学行为。不仅如此,二甲双胍的抗肿瘤临床研究也不断出现,包括大样本回顾性研究和前瞻性研究。这些研究数据不仅为二甲双胍抗肿瘤效应提供了有益的证据支持,也为二甲双胍及其介导的抗肿瘤分子信号途径的阐明奠定了理论依据。

Basic and Clinical Research Progress of Metformin in Anti-tumor Effects

Metformin, an insulin sensitizer, is a biguanide commonly used to treat type 2 diabetes mellitus. Emerging evidencesuggests that metformin may activate AMPK and inhibit mTOR signaling to exert anti-tumor effects and inhibit tumor cells growth.Metformin also plays some roles on cell cycle, apoptosis, and angiogenesis of tumor cells. Moreover, anti-tumor clinical studies ofmetformin are more and more, including retrospective study of large sample and prospective study. These studies not only provide helpfulevidence for anti-tumor effects of metformin, but also give the theoretical basis for clarifying the molecular signal pathway of anti-tumorinduced by metformin.